UBC Medical Indonesia (LABS) Fundamentals 2026 — P/E 48.7x, Revenue Analysis | SniperIQ
UBC Medical Indonesia (LABS) is a ID-listed Healthcare company in Medical - Equipment & Services with a market capitalization of Rp580.6B, trading at Rp147.00 on the JKT. This SniperIQ fundamentals page covers UBC Medical Indonesia's valuation (P/E 48.7x, P/B 5.7x), profitability (net margin 5.9%), revenue (Rp199.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is UBC Medical Indonesia's market cap?
UBC Medical Indonesia (LABS) has a market capitalization of approximately Rp580.6B, trading at Rp147.00 on the JKT. Market cap moves with the live share price.
What is UBC Medical Indonesia's P/E ratio?
UBC Medical Indonesia's trailing twelve-month P/E ratio is 48.7x, with a price-to-book (P/B) of 5.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is UBC Medical Indonesia?
UBC Medical Indonesia runs a net profit margin of 5.9%, a gross margin of 34.5%, and an operating margin of 8.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does UBC Medical Indonesia generate?
UBC Medical Indonesia reported revenue of Rp199.3B for fiscal year 2025, with net income of Rp13.5B and earnings per share (EPS) of 2.29. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does UBC Medical Indonesia pay a dividend?
UBC Medical Indonesia does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is UBC Medical Indonesia financially healthy?
UBC Medical Indonesia carries a debt-to-equity ratio of 0.18x and a current ratio of 2.75x, with a market beta of -0.15. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is UBC Medical Indonesia a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For UBC Medical Indonesia (LABS) the key facts are: market cap Rp580.6B, P/E 48.7x, revenue Rp199.3B, 52-week range 120-260. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track UBC Medical Indonesia's full fundamentals live
Get UBC Medical Indonesia's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.